

## 086

**Long-term monitoring of 340 patients with a cardiac resynchronization therapy: Evaluation of responders, super-responders and non-responders**

Pascal Defaye (1), Nicolas Demede (1), Peggy Jacon (1), Adama Kane (1), Blandine Mondesert (1), Marc Hero (2)  
(1) *CHU Grenoble, Grenoble, France* – (2) *Medtronic France, Boulogne Billancourt, France*

The main objective of this retrospective study is to analyze the future of heart failure patients, refractory to optimal pharmacological treatment, implanted by a bi-ventricular pacemaker (CRT-P) or defibrillator (CRT-D).

**Methods:** 340 patients were implanted between the 1<sup>st</sup> January 1999 and 31 December 2007, aged 69 +/-10 years mainly men (80%). The total population presented in part ischemic heart disease (56%), NYHA class III (79%) and an indication of primary prevention (76%). The number of hospitalization in the 6 months prior to implantation is an average of 1 +/- 1. The population was divided into 3 groups:

Group 1: 194 patients responders [R] (decrease of NYHA class, or stable NYHA and decreasing hospitalization, or the latter stable and increasing the LVEF of more than 10%, 6 months after implantation),  
Group 2: 84 patients not responders [NR] (do any of the above criteria),  
Group 3: 62 patients very good responders [SR] with the increasing LVEF greater than 15%.

**Results:** The comparison between the 3 groups showed a significant difference for the follow parameters: the NYHA class ([NR] 2.8 +/- 0.6 vs [R] 2.0 +/- 0.4 vs [SR] 1.8 +/- 0.5), the number of hospitalization ([NR] 1.1 +/- 1.3 vs [R] 0.2 +/- 0.5 vs [SR] 0.1 +/- 0.3), LVEF ([NR] 29 +/- 9 vs [R] 33 +/- 8 vs [SR] 47 +/- 8). The curves of Kaplan-Meier show a significant difference in survival rates for non-responders, responders and good responders (Logrank p <0.001).

**Discussion:** Treatment with bi-ventricular stimulation shows that 75% of patients are improved compared to the criteria usually measured. The study reveals a group of very good responders representing 18% of the total population with a survival rate at 5 years over 65%.

## 087

**Oxidative stress implication in cardiogenic shock with ischemic or idiopathic severe left ventricular dysfunction: role of etiologies of cardiomyopathies**

Jean-Christophe Charniot (1), Claudine Cosson (2), Franck Chemouni (1), Noelle Vignat (3), Vera Bogdanova (1), Rachid Kidouche (1), Jean-Jacques Monsuez (4), Jean-Yves Artigou (5), Jean-Paul Albertini (1)  
(1) *Hôpital Avicenne, Cardiologie, Bobigny, France* – (2) *hopital Bicetre, Kremlin Bicetre, France* – (3) *Hôpital Avicenne, Cardiologie, Bobigny, France* – (4) *Hopital René Muret, Sevran, France* – (5) *Hopital Avicenne, Bobigny, France*

**Background:** Oxidative stress (OS) implication is paramount in pathology: ischemia reperfusion sequence (acute coronary syndrome, cardiac surgery, transplantation). Involvement of OS in heart failure (HF) is less known but is increased in the failing heart, and this might contribute to the pathogenesis of myocardial remodeling and HF.

**Aim:** Prospective study to identify OS in plasma from patients with a cardiogenic shock and to evaluate the role of etiologies of cardiomyopathy: ischemia or no.

**Methods:** Consecutive patients hospitalized in the cardiology unit with a first cardiogenic shock that complicated an idiopathic or ischemic dilated cardiomyopathy (DCM) with left ventricular (LV) dysfunction.

**Exclusion criteria:** known cardiomyopathy, acute coronary syndrome, septic or anaphylactic or hypovolemic shock, treatment with angiotensin converting enzyme inhibitors (ACEI) or angiotensin II antagonists (AA II).

OS was evaluated in blood samples at the admission (T<sub>0</sub>) and one month later: thiobarbituric acid-reactive substances (TBARS), total antioxidant status (TAS), protein carbonyls (PC) and LDL oxidized; superoxide dismutase (SOD), glutathione peroxidase (GSH) and GSSG/GSH) and catalase activities; plasma  $\alpha$  tocopherol, vitamin A and  $\beta$  carotene.

**Results:** 23 consecutive patients (90% men), mean age 59±11y. Follow-up of 15 months. The aetiologies of CMD were ischemic (n=6), idiopathic (n=15), toxic (n=1) or restrictive (n=1). The mean LV ejection fraction was 23.3±8%. The NT-proBNP level was 9600±2000ng/ml.

	T <sub>0</sub>	1 MONTH	NORMAL VALUE
PC ( $\mu$ mol/g prot)	0.16 (0.05-0.41)	0.14 (0.07-0.29)	< 0.10
TBARS (nmol/gHb)	2.2 (1.3-17.3)	2.5 (1.1-6.5)	0.7-1.6
LDLox (UI/L)	48 (20-83)	49 (26-98)	16-18
GSH ( $\mu$ mol/g Hb)	2.1 (0.8-3.1)	2.2 (1.7-4)	3.3-6.9
GSSG/GSH	0.19 (0.09-0.93)	0.13 (0.07-0.29)	< 0.08

Acute heart failure was associated with an increased OS. OS was more important in patients with arrhythmia.

**Conclusion:** Acute heart failure increased the level of oxygen free radicals. We hypothesized that modifications of OS could be implied in arrhythmias and complications of acute heart failure.

## 088

**Prescription of beta blockers at hospital discharge and beyond, in patients with heart failure. Results from the DEVENIR study**

Alain Cohen Solal (1), Patrick Assyag (2), Christine Contre (3), Maxime Guenoun (4), Leurs Irina (3), Pascal Poncelet (4), Pierre Louis Prost (5), Jean Francois Thebaut (4)

(1) *LARIBOISIERE, Paris, France* – (2) *SAINT ANTOINE, Paris, France* – (3) *MENARINI, Rungis, France* – (4) *CNCF, Paris, France* – (5) *Discovery Cascade, Paris, France*

**Rationale:** Beta blockers are a corner stone treatment of heart failure (HF) in patients with altered systolic function (LVEF<40%). Guidelines are less clear for HF patients with preserved systolic function (LVEF>50%) or for patients belonging to the "grey zone" (LVEF 40-50%).

**Objectives:** to describe the prescription rate of beta-blockers in HF patients.

**Methods:** Cross sectional observational survey with retrospective collection of data at hospital discharge. Patients must have been diagnosed with CHF and have been hospitalised for CHF within the previous 18 months. Patients are classified according to the LVEF at hospital discharge.

**Results:** 1 452 patients were included by 412 French outhospital cardiologists. 1137 with known LVEF at hospital discharge have had at least one visit by the cardiologist between hospital discharge (mean delay 5.76±4.51 months). In a multivariate model, BB prescription was more frequent in HF from ischemic origin (OR=1.39) or with dilated cardiomyopathy (OR=1.44) and less frequent in older patients (OR=0.97 per year) and in case of asthma/COPD (OR=0.31 and if FEVG was >50% (OR=0.62).

	LVEF < 40% N=661	LVEF 40-50% N=282	LVEF > 50% N=194	Total N=1137
<b>At hospital discharge/at entry in the survey</b>				
BB	78%/83%	78%/85%	62%/70%	76%/82%
Recommended BB†	75%/77%	72%/74%	54%/62%	71%/74%
Reaching the target dose	8%/16%	7%/16%	7%/13%	7%/15%
<b>Changes since discharge</b>				
BB added*	28%	34%	25%	28%
BB stopped**	1%	1%	2%	1%
BB dose increased*	27%	27%	17%	25%
BB dose decreased	4%	1%	3%	3%

†metoprolol, nebivolol, bisoprolol, carvedilol ;

\*percentage calculated in patients without BB at hospital discharge (N=278);

\*\* percentage calculated in patients with BB at hospital discharge (N=859).